FDA Hearing on Psychedelics Zeroes In on Access, Training and Safety Requirements

# Why the FDA convened the hearing The agency held a public hearing as it approaches what many expect will be the first approval of a psychedelic medicine. The goal was to collect input on practical questions that will shape how approved psychedelic therapies are delivered, monitored and studied after approval.

# The central debate: access vs. clinical model

Companies such as Compass Pathways and Definium Therapeutics have seen trial success using the DSM approach. Definium reported three phase 3 wins in 12 weeks and Compass is pursuing a rolling NDA after pivotal wins. Proponents argue this isolates the drug's clinical effects for regulatory evaluation.

# Calls to preserve psychotherapy and define workforce standards Several clinician speakers pressed the FDA to recognize psychotherapy as part of effective treatment. A clinical psychologist cited trials showing better outcomes when psychedelics are combined with therapy. Others running education and credentialing programs urged that workforce readiness, transparent training standards and prepared clinicians be required for safe delivery.

There was disagreement about whether a new specialized workforce is necessary. Some, including a nurse practitioner, argued existing licensed clinicians can safely and immediately provide care. Others urged psychiatric oversight. A psychiatrist asked the FDA to require clinical oversight by psychiatrists for psychiatric indications, highlighting the need for thorough diagnostic evaluation and the ability to identify and manage complications.

# The 15‑minute on‑call physician rule and rural access

# Safety oversight and ongoing study Speakers generally supported continued study and monitoring, noting the need to track real‑world outcomes. Many expected that post‑approval controls such as Risk Evaluation and Mitigation Strategies (REMS) would shape delivery. Discussion touched on who should set training standards, how credentials should be verified, and what clinical expertise is required to manage risks specific to psychedelics.

# A reminder about risks and the approval process Near the end of the hearing, a speaker with a drug policy background cautioned that psychedelics must meet the same approval standards as any drug. That comment signaled attention to both safety data and how regulatory decisions are perceived as the field moves toward clinical availability.

# What this means next The FDA will use the public input to refine post‑approval expectations: provider credentials, supervision rules, physician availability standards, and potential REMS. Decisions on those items will determine how widely and quickly patients can access FDA‑approved psychedelic treatments and what settings will be authorized to provide them.